0001539497-24-000104.txt : 20240124 0001539497-24-000104.hdr.sgml : 20240124 20240124160027 ACCESSION NUMBER: 0001539497-24-000104 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240124 ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240124 DATE AS OF CHANGE: 20240124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BELLICUM PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0001358403 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 201450200 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36783 FILM NUMBER: 24556375 BUSINESS ADDRESS: STREET 1: 3730 KIRBY DRIVE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 BUSINESS PHONE: (832) 384-1100 MAIL ADDRESS: STREET 1: 3730 KIRBY DRIVE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 FORMER COMPANY: FORMER CONFORMED NAME: BELLICUM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060405 8-K 1 n3936_x2-8k.htm 8-K
false 2024-01-24 --12-31 0001358403 0001358403 2024-01-24 2024-01-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 24, 2024

 

 

 

Bellicum Pharmaceuticals, Inc. 

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36783   20-1450200
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

3730 Kirby Drive, Ste. 1200, Houston, TX 77098

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: 281-454-3424 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

   

 

Item 3.02 Unregistered Sales of Equity Securities.

 

On January 24, 2024, the Board of Directors (the “Board”) of Bellicum Pharmaceuticals, Inc. (the “Company”) authorized the issuance of one (1) share of Series A Junior Preferred Stock, par value $0.01 per share (the “Super-Voting Share”) to Richard A. Fair, a current director of the Company, for the purchase price of $0.01.

 

The Company relied upon an exemption from registration in accordance with Section 4(a)(2) of the Securities Act of 1933. The Company was able to rely upon this exemption because this issuance does not constitute a public offering of its shares.

 

Reference is made to the information regarding the Super-Voting Share disclosed in Item 5.03 of this Current Report on Form 8-K, which is incorporated by reference into this Item 3.02.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On January 24, 2024, the Company filed a Certificate of Designation of Series A Junior Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware with respect to the Super-Voting Share.

 

The rights, preferences and privileges of the Super-Voting Share are set forth in the Certificate of Designation. The Super-Voting Share entitles the holder thereof to cast on each matter submitted for stockholder approval at the Adjourned Special Meeting (as defined herein) a number of votes equal to the number of shares of common stock of the Company (the “Common Stock”) outstanding on the record date for the Adjourned Special Meeting, provided that the holder casts such votes in a manner that is proportionate to the manner in which all shares of Common Stock present, in person or by proxy, at the Adjourned Special Meeting are voted with respect to such matter. The votes cast by the Super-Voting Share shall thus be “for,” “against,” and “abstain” (if any) with respect to the proposals being voted on at the Adjourned Special Meeting in amounts proportionate to the aggregate voting results of the Common Stock present, in person or by proxy at the Adjourned Special Meeting with respect to such proposals.

 

The Super-Voting Share shall rank (i) senior to the Common Stock and any other class or series of capital stock established by the Company in the future, the terms of which specifically provide that such series ranks junior to the Series A Junior Preferred Stock as to the distribution of assets upon the Company’s liquidation, dissolution or winding up, (ii) on parity with any class or series of capital stock that the Company may establish in the future the terms of which specifically provide that such class or series ranks on parity with the Series A Junior Preferred Stock with respect to the distribution of assets upon the Company’s liquidation, dissolution or winding up, and (iii) junior to the Company’s Series 1 Redeemable Convertible Non-Voting Preferred Stock, Series 2 Redeemable Convertible Non-Voting Preferred Stock, Series 3 Redeemable Convertible Non-Voting Preferred Stock and any other class or series of capital stock established by the Company in the future.

 

The holder of the Super-Voting Share is not entitled to receive dividends. Subject to the prior rights of any other class or series of capital stock of the Company, upon a liquidation, dissolution or winding up of the Company, the holder of the Super-Voting Share will be entitled to $0.01 (payable out of funds legally available therefor) before any distribution or payment shall be made to the holders of Common Stock.

 

The holder of the Super-Voting Share may not transfer such share or any interest in such share to any other person or entity without the prior consent of the Board.

 

This description of the Super-Voting Share does not purport to be complete and is qualified in its entirety by reference to the text of the Certificate of Designation for the Super-Voting Share, a copy of which is filed as Exhibit 3.1 to this report this Current Report on Form 8-K and is incorporated herein by reference.

 

On January 24, 2024, the Board approved the amendment of Article III, Section 8 of the Company’s bylaws to enable the holders of a majority of the voting power of, rather than the majority of, the outstanding shares of stock of the Company entitled to vote at a meeting of stockholders to constitute a quorum for the transaction of business.

 

   

 

This description of the amendment to the Company’s bylaws does not purport to be complete and is qualified in its entirety by reference to the text of the amendment, a copy of which is filed as Exhibit 3.2 to this report this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference.

 

Item 8.01 Other Events.

 

On January 24, 2024, the Company convened its special meeting of stockholders (the “Special Meeting”) for the purpose of approving (i) the Asset Purchase Agreement, dated November 21, 2023 (such agreement, as amended on December 8, 2023 pursuant to that certain Amendment No. 1 to Asset Purchase Agreement and as it may be further amended, modified or supplemented from time to time, the “Asset Purchase Agreement”), by and among the Company and The University of Texas M. D. Anderson Cancer Center, an institution of higher education and an agency of the State of Texas (“MDACC”), which provides for the sale to MDACC of certain assets, including all rights to each program of research and development related to (a) CaspaCIDe (inducible caspase-9), the Rimiducid-inducible safety switch designed to abrogate high-grade adverse events associated with genetically-modified cell therapies, (b) inducible MyD88/CD40 (iMC), the Rimiducid-inducible activation switch designed to enhance effector cell proliferation and persistence and to resist exhaustion and inhibitory signals, (c) dual-switch GoCAR-T, incorporating both iMC and a modified rapalog-inducible caspase-9 safety switch, and (d) Rimiducid (the “Asset Sale”), and may be deemed under Delaware law to be a sale of substantially all of our assets, and the consummation of the other transactions contemplated by the Asset Purchase Agreement (the “Asset Sale Proposal”) and (ii) subject to approval of the Asset Sale Proposal, the liquidation and dissolution of the Company in accordance with Section 275 of the Delaware General Corporation Law (the “Dissolution”) and pursuant to the Plan of Dissolution attached to the information statement previously distributed to the Company’s stockholders in connection with the Special Meeting (the “Plan of Dissolution”) (the “Dissolution Proposal”). There were 4,132,740 shares of Common Stock present or represented by proxy at the Special Meeting, which did not constitute a quorum under the Company’s bylaws.

 

Accordingly, the Special Meeting was adjourned without any business being conducted in order to allow time to achieve a quorum and to allow the Company’s stockholders additional time to vote on the Asset Sale Proposal and Dissolution Proposal. The Company will file a Current Report on Form 8-K to report when the adjourned Special Meeting (the “Adjourned Special Meeting”) will be held.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Current Report on Form 8-K contains “forward-looking statements” which include, but are not limited to, all statements that do not relate solely to historical or current facts, such as statements regarding the Company’s expectations, intentions or strategies regarding the future, the timing and outcome of the Adjourned Special Meeting, and the completion or effects of the Asset Sale and the Dissolution. In some cases, these statements include words like: “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the Company obtaining the requisite stockholder vote to approve the Asset Sale and the Dissolution, the ability of the parties to consummate the Asset Sale, satisfaction of closing conditions precedent to the consummation of the Asset Sale, potential delays in consummating the Asset Sale, the ability of the Company to timely execute the Dissolution, the execution costs to the Company of the Asset Sale and the Dissolution, the extent of other liabilities that the Company will be required to satisfy or reserve for in connection with the Dissolution, the impact of these costs and other liabilities on the cash, property and other assets available for distribution to the stockholders in the Dissolution, the amount of cash (if any) that will be distributed to the stockholders in connection with the Asset Sale and the Dissolution, and outcomes to the stockholders if the Asset Sale Proposal and/or the Dissolution Proposal are not approved by the requisite stockholders at the Special Meeting. Additional risks and uncertainties that could cause actual outcomes and results to differ

   

 

materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in the Company’s most recent filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 and any subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov.

 

The forward-looking statements included in this information statement are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Number        Description of Exhibits
3.1   Certificate of Designation of Senior A Junior Preferred Stock of Bellicum Pharmaceuticals, Inc., dated January 24, 2024.
3.2   Amendment to Amended and Restated Bylaws of Bellicum Pharmaceuticals, Inc., effective January 24, 2024.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

   

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Bellicum Pharmaceuticals, Inc.

     

Dated: January 24, 2024

By:

  

/s/ Richard A. Fair

      Richard A. Fair
      Principal Executive and Financial Officer

 

 

 

 

   

 

 EX-3.1 2 exh3-1.htm CERTIFICATE OF DESIGNATION OF SENIOR A JUNIOR PREFERRED STOCK OF BELLICUM PHARMACEUTICALS, INC., DATED JANUARY 24, 2024

Exhibit 3.1

 

CERTIFICATE OF DESIGNATION OF
SERIES A JUNIOR PREFERRED STOCK OF
BELLICUM PHARMACEUTICALS, INC.

Bellicum Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), does hereby certify that, pursuant to the authority conferred upon the Board of Directors by the Amended and Restated Certificate of Incorporation of the Corporation (as amended and/or restated from time to time, the “Certificate”), and pursuant to Section 151 of the Delaware General Corporation Law (the “DGCL”), the Board of Directors of the Corporation (the “Board of Directors”) adopted the following resolution, which resolution remains in full force and effect on the date hereof:

RESOLVED, that pursuant to the authority expressly granted to and vested in the Board of Directors by the provisions of the Certificate and the Amended and Restated Bylaws of the Corporation (the “Bylaws”), and in accordance with Section 151 of the DGCL, there is hereby created, out of the 7,882,500 shares of Preferred Stock, par value $0.01 per share (the “Preferred Stock”), of the Corporation remaining authorized, unissued and undesignated, one (1) share of Series A Junior Preferred Stock, par value $0.01 per share, which share shall be uncertificated and have the following powers, designations, preferences and relative, participating, optional or other rights, and qualifications, limitations or restrictions thereof:

(1)       Voting. Except as provided in this Section (1) or as required by law, the Series A Junior Preferred Stock shall not entitle the holder thereof, as such, to vote on any matter. At any meeting of stockholders at which the dissolution of the Corporation is submitted to a vote of the holders of Common Stock (a “Dissolution Meeting”), (i) the Series A Junior Preferred Stock shall entitle the holder thereof, as such, to vote together with the holders of Common Stock (and any other class or series of capital stock of the Corporation entitled to vote thereon together with the Common Stock), as a single class, on any matter submitted to a vote of the holders of Common Stock (other than the election of directors), and (ii) the voting power of the Series A Junior Preferred Stock with respect to any matter submitted to a vote of the holders of Common Stock thereat (other than the election of directors) shall be determined in accordance with clauses (a), (b) and (c) of this Section (1).

(a)       To the extent the holder of the Series A Junior Preferred Stock votes in accordance with the following formula, on each matter submitted to a vote of the holders of Common Stock at a Dissolution Meeting (other than the election of directors), the Series A Junior Preferred Stock shall entitle the holder thereof, as such, to cast a number of votes equal to the number of shares of Common Stock outstanding on the record date for determining the stockholders entitled to vote at such Dissolution Meeting (such number of votes, the “Votes”):

The holder of the Series A Junior Preferred Stock shall cast the Votes in a manner that is proportionate to the manner in which all shares of Common Stock present, in person or by proxy, at such Dissolution Meeting are voted with respect to such matter, such that the Votes shall reflect the voting results with respect to “shares voted for,” “shared voted against,” and “shares abstained” (if any)

   

 

proportionate to such aggregate voting results of the Common Stock present, in person or by proxy, on such matter.

(b)       In the event the holder of the Series A Junior Preferred Stock purports to cast, in person or by proxy, the Votes on any matter at such Dissolution Meeting in a manner other than as provided in clause (a) of this Section (1), then such clause shall not apply with respect to such matter, and the Series A Junior Preferred Stock shall not entitle the holder thereof, as such, to vote on such matter; provided, however, that, notwithstanding this clause (b), for purposes of determining the existence of a quorum at a Dissolution Meeting, the Series A Junior Preferred Stock shall be deemed to entitle the holder thereof, as such, to have the voting power that is equal to the Votes.

(c)       Notwithstanding the foregoing clauses (a) and (b) of this Section 1, following the receipt of stockholder approval of the dissolution of the Company at a Dissolution Meeting, the Series A Junior Preferred Stock Junior shall not entitle the holder thereof, as such, to vote on any matter, except as required by law.

(2)       Ranking. The Series A Junior Preferred Stock shall, with respect to rights upon a liquidation, dissolution or winding up of the Corporation, rank (i) senior to the Common Stock and any other class or series of capital stock established by the Corporation in the future, the terms of which specifically provide that such series ranks junior to the Series A Junior Preferred Stock as to the distribution of assets upon the Corporation’s liquidation, dissolution or winding up, (ii) on parity with any class or series of capital stock that the Corporation may establish in the future the terms of which specifically provide that such class or series ranks on parity with the Series A Junior Preferred Stock with respect to the distribution of assets upon the Corporation’s liquidation, dissolution or winding up, and (iii) junior to the Series 1 Redeemable Convertible Non-Voting Preferred Stock, the Series 2 Redeemable Convertible Non-Voting Preferred Stock, the Series 3 Redeemable Convertible Non-Voting Preferred Stock and any other class or series of capital stock established by the Corporation in the future, the terms which specifically provide that such class or series ranks senior to the Series A Junior Preferred Stock as to the distribution of assets upon the Corporation’s liquidation, dissolution or winding up.

(3)       Dividends and Liquidating Distributions. No dividends shall be paid on the Series A Junior Preferred Stock. Subject to the prior rights of any other class or series of capital stock of the corporation, upon a liquidation, dissolution or winding up of the Corporation, the Series A Junior Preferred Stock shall entitle the holder thereof, as such, to $0.01 (payable out of funds legally available therefor) before any distribution or payment shall be made to the holders of Common Stock. Solely for purposes of this paragraph, neither the sale of all or substantially all of the assets or capital stock of the Corporation, nor the merger or consolidation of the Corporation with any other entity, shall be deemed to be a dissolution, liquidation or winding up of the Corporation.

(4)       Transfer Restriction. The holder of the Series A Junior Preferred Stock shall not, directly or indirectly, transfer such share or any interest in such share (by sale, assignment, encumbrance, hypothecation, pledge, conveyance in trust, gift, bequest, devise or descent, by operation of law or by any other transfer or disposition of any kind, including to any receivers, creditors, trustees in bankruptcy or other insolvency proceeding) to any other person or entity

   

 

without the prior consent of the Board of Directors. A purported transfer in violation of this paragraph shall be null and void ab initio. The notice required by Section 151(f) of the Delaware General Corporation Law, shall contain a conspicuous legend of the restriction contemplated by this paragraph.

(5)       Amendments. In addition to any vote required by law or provided by the Certificate, any amendment to the provisions of this Certificate of Designation shall require the approval of the holder of the Series A Junior Preferred Stock, voting as a separate class.

* * * * *

   

 

In witness whereof, the undersigned Corporation has caused this Certificate to be signed by a duly authorized officer on the date set forth below.

  BELLICUM PHARMACEUTICALS, INC.
   
  By:  /s/ Richard A. Fair
  Name:
Title: 		Richard A. Fair
President and Chief Executive Officer

 

  Dated: January 24, 2024
     

 

 

   

 EX-3.2 3 exh3-2.htm AMENDMENT TO AMENDED AND RESTATED BYLAWS OF BELLICUM PHARMACEUTICALS, INC., EFFECTIVE JANUARY 24, 2024

Exhibit 3.2 

 

AMENDMENT TO

AMENDED AND RESTATED

BYLAWS

OF

BELLICUM PHARMACEUTICALS, INC.

 

The Amended and Restated Bylaws (the “Bylaws”) of Bellicum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), are hereby amended as follows:

Article III, Section 8 of the Bylaws is hereby amended and restated in its entirety as follows:

“Section 8. Quorum. At all meetings of stockholders, except where otherwise provided by statute or by the corporation’s Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”), or by these Bylaws, the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of a majority of the voting power of the outstanding shares of stock entitled to vote thereat shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairman of the meeting or by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by statute or by applicable stock exchange rules, or by the Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the affirmative vote of the majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders. Except as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the election of directors. Where a separate vote by a class or classes or series is required, except where otherwise provided by the statute or by the Certificate of Incorporation or these Bylaws, a majority of the outstanding shares of such class or classes or series, present in person, by remote communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled to take action with respect to that vote on that matter. Except where otherwise provided by statute or by the Certificate of Incorporation or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of shares of such class or classes or series present in person, by remote communication, if applicable, or represented by proxy at the meeting shall be the act of such class or classes or series.”

   

 

 EX-101.SCH 4 blcm-20240124.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 blcm-20240124_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 blcm-20240124_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 24, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 24, 2024
Current Fiscal Year End Date --12-31
Entity File Number 001-36783
Entity Registrant Name Bellicum Pharmaceuticals, Inc.
Entity Central Index Key 0001358403
Entity Tax Identification Number 20-1450200
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3730 Kirby Drive
Entity Address, Address Line Two Ste. 1200
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77098
City Area Code 281
Local Phone Number 454-3424
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
XML 8 n3936_x2-8k_htm.xml IDEA: XBRL DOCUMENT 0001358403 2024-01-24 2024-01-24 iso4217:USD shares iso4217:USD shares false 2024-01-24 --12-31 0001358403 8-K 8-K 2024-01-24 Bellicum Pharmaceuticals, Inc. Bellicum Pharmaceuticals, Inc. DE DE 001-36783 001-36783 20-1450200 20-1450200 3730 Kirby Drive Ste. 1200 Houston TX 77098 281 281 454-3424 454-3424 false false false false false false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 21 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bellicum.com/role/Cover Cover Cover 1 false false All Reports Book All Reports blcm-20240124.xsd blcm-20240124_lab.xml blcm-20240124_pre.xml n3936_x2-8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "n3936_x2-8k.htm": { "nsprefix": "BLCM", "nsuri": "http://bellicum.com/20240124", "dts": { "schema": { "local": [ "blcm-20240124.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "blcm-20240124_lab.xml" ] }, "presentationLink": { "local": [ "blcm-20240124_pre.xml" ] }, "inline": { "local": [ "n3936_x2-8k.htm" ] } }, "keyStandard": 21, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 34 }, "report": { "R1": { "role": "http://bellicum.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-24", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "n3936_x2-8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-24", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "n3936_x2-8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bellicum.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001539497-24-000104-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001539497-24-000104-xbrl.zip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end